Zymeworks gains on up to $813 million Roche licensing deal for lung cancer drug

Zymeworks licensed its experimental lung cancer drug ZW209 to Roche in a global deal worth up to $813 million, including $55 million upfront and potential milestone payments and royalties. Zymeworks shares rose 2.8% premarket.